RecruitingPhase 3NCT05378399

SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder

SmartSteps: A Context-Aware, Pre-Exposure Prophylaxis Adherence Intervention for Individuals With Substance Use Disorder


Sponsor

Brigham and Women's Hospital

Enrollment

40 participants

Start Date

Dec 20, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

This is a single-arm, observational study of HIV-negative MSM with substance use disorder. Those who meet pre-screening criteria will attend a Screening Visit (Visit 1), where the informed consent process will be conducted and study eligibility will be confirmed. Eligible participants will attend three additional visits over the course of the study - the Enrollment Visit (Visit 2), Month 1 Visit (Visit 3), and Month 2 Visit (Visit 4). Participants will take one PrEP digital pill per day, for 60 days total, while using the digital pill system (DPS) and Beiwe, a digital phenotyping app. On nonadherent days, participants will receive brief surveys prompting them to report the reasons for their missed dose, as well as their engagement in substance use and sexual activity. Timeline followback will be conducted at the Month 1 and Month 2 Visits to understand the context of any nonadherence. Qualitative user experience exit interviews and dried blood spots (DBS) will be conducted at the Month 2 Visit.


Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a smartphone-based app (SmartSteps) designed to help gay and bisexual men who use substances stay adherent to PrEP — a daily medication that prevents HIV infection. **You may be eligible if...** - You are a cisgender male, 18 or older, who has sex with men - You are HIV negative and currently on or starting PrEP (the HIV-prevention pill) - You use substances at a moderate or higher risk level (based on screening) - You own a smartphone (Android or iOS) - Your kidney and liver function are adequate for PrEP use **You may NOT be eligible if...** - You do not speak English - You have a history of Crohn's disease, ulcerative colitis, gastric bypass, bowel stricture, or abdominal radiation or cancer (which may affect how PrEP is absorbed) - You are allergic to gelatin, silver, zinc, or PrEP itself - You are unwilling to use the digital tracking device required by the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDescovy or Truvada

Descovy or Truvada prescribed with digital pills for PrEP

DEVICEID-Cap System

Digital pills overencapsulating Descovy or Truvada for PrEP

DEVICEBeiwe

Digital phenotyping app


Locations(1)

Fenway Health

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05378399


Related Trials